Patents by Inventor Adrien Weingaertner

Adrien Weingaertner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20260078372
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: July 8, 2025
    Publication date: March 19, 2026
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220170016
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 2, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220002722
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 6, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Flauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum